​Radient Technologies Inc. Files Provisional Patent Application for Reducing Nicotine Levels in Tobacco

Spotlight Companies  |

Radient Technologies Inc. (TSX Venture:RTI) is pleased to announce that it has filed a provisional patent application with the U.S. Patent and Trademark Office (the “USPTO”) for innovation related to methods for obtaining nicotine depleted tobacco, without materially altering certain desirable properties of the tobacco.

Click to enlarge

The patent application provides a method to selectively extract nicotine from tobacco via Radient’s continuous-flow microwave-assisted processing (MAP™) extraction technology and provides a composition of tobacco that is depleted in nicotine, but retains its appearance and organoleptic properties.

The invention discloses the ability of Radient’s proprietary MAP™ technology to achieve nicotine depletions of over 95% across multiple cured tobacco types, leaving the reduced nicotine tobacco intact and fit for processing into cigarettes and other combustible tobacco products.

This provisional application was first filed in the USPTO to create a priority date and allow for future filings in other selected jurisdictions, as appropriate.

The U.S. Food and Drug Administration (the “FDA”) issued an Advanced Notice of Proposed Rulemaking (ANPRM) on March 16, 2018 to explore a product standard to set the maximum nicotine level for cigarettes, so that cigarette products are minimally addictive or non-addictive. Radient is supportive of the FDA’s proposal and believes that the subject of the invention for which it has filed this provisional patent could provide a feasible solution to the reduction of nicotine from tobacco at industrially relevant volumes, while avoiding the need to implement complicated and time-consuming changes to the tobacco agricultural supply chain.

The patent application also includes methods of recovering and purifying the nicotine as a co-product. Nicotine has commercial value for inclusion in smoking cessation products and in e-liquids for use in e-cigarettes and vaping products.

Dr. Steven Splinter, Founder and CTO of Radient, stated: “Radient is committed to innovation in new and developing industries, and we see the potential market opportunity in providing a safe, effective industrial-scale method of nicotine extraction from tobacco, specifically during the primary manufacturing phase of cigarettes or other combustible tobacco products. Furthermore, a high-purity nicotine co-product could have wide-scale applications in the growing smoking cessation product market.”

About Radient
Radient extracts natural compounds from a range of biological materials using microwave assisted processing (“MAP™”), a patented technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health and personal care markets. Since 2016, Radient has expanded its offerings to enter the cannabinoids market utilizing its MAP™ platform to process and extract cannabinoids including cannabidiol and tetrahydrocannabinol from cannabis biomass. Visit www.radientinc.com for more information.

In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Trending Articles

Bond Yields Have Risen Well Above Stock Dividend Yields. Are They a Buy?
We're at the Tail End of a Classic Video Game Stock Bust
Is Gold Really the Right Place for Your Money?
How Companies Can Succeed in AI Winter: Jeff Kagan
Utility Investing Is a Steady, Buy-and-Hold Play. Just Not in This Market
Why Nuclear Energy Is Now Part of The Road to Renewables
Our Inflation Nightmare Will Flatline in Six Months

Market Movers

Sponsored Financial Content